NY State Senate Bill 2015-S6962

Senate Bill S6962

Vetoed By Governor

2015-2016 Legislative Session

Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology

download bill text pdf

Archive: Last Bill Status - Vetoed by Governor

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Vetoed By Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Nov 28, 2016	vetoed memo.283
Nov 16, 2016	delivered to governor
Jun 16, 2016	returned to senate passed assembly ordered to third reading rules cal.461 substituted for a10478
May 17, 2016	referred to insurance delivered to assembly passed senate
May 16, 2016	ordered to third reading cal.851 committee discharged and committed to rules
May 11, 2016	print number 6962a
May 11, 2016	amend (t) and recommit to health
Mar 10, 2016	referred to health

Votes

- May 17, 2016 - Floor Vote
  S6962
  
  57
  
  Aye
  
  1
  
  Nay
  
  0
  
  Absent
  
  5
  
  Excused
  
  0
  
  Abstained
  - - Floor Vote: May 17, 2016
      
      aye (57)
      
      Addabbo Jr.
      
      Akshar
      
      Amedore
      
      Avella
      
      Bonacic
      
      Boyle
      
      Carlucci
      
      Comrie
      
      Croci
      
      DeFrancisco
      
      Dilan
      
      Espaillat
      
      Farley
      
      Felder
      
      Flanagan
      
      Funke
      
      Gallivan
      
      Gianaris
      
      Golden
      
      Griffo
      
      Hannon
      
      Hassell-Thompson
      
      Hoylman-Sigal
      
      Kaminsky
      
      Kennedy
      
      Klein
      
      Krueger
      
      LaValle
      
      Lanza
      
      Larkin
      
      Latimer
      
      Little
      
      Marcellino
      
      Martins
      
      Montgomery
      
      Murphy
      
      O'Mara
      
      Ortt
      
      Panepinto
      
      Parker
      
      Peralta
      
      Perkins
      
      Persaud
      
      Ranzenhofer
      
      Ritchie
      
      Rivera
      
      Robach
      
      Sanders Jr.
      
      Savino
      
      Serino
      
      Serrano
      
      Squadron
      
      Stavisky
      
      Stewart-Cousins
      
      Valesky
      
      Venditto
      
      Young
      
      nay (1)
      
      Hamilton
      
      excused (5)
      
      Breslin
      
      Diaz
      
      Marchione
      
      Nozzolio
      
      Seward
  May 16, 2016 - Rules Committee Vote
  S6962
  
  24
  
  Aye
  
  0
  
  Nay
  
  1
  
  Aye with Reservations
  
  0
  
  Absent
  
  0
  
  Excused
  
  0
  
  Abstained
  - - Rules Committee Vote: May 16, 2016
      
      aye (24)
      
      Bonacic
      
      Breslin
      
      Carlucci
      
      DeFrancisco
      
      Espaillat
      
      Farley
      
      Flanagan
      
      Gianaris
      
      Golden
      
      Hannon
      
      Hassell-Thompson
      
      Krueger
      
      LaValle
      
      Lanza
      
      Larkin
      
      Little
      
      Marcellino
      
      Montgomery
      
      Parker
      
      Perkins
      
      Robach
      
      Stewart-Cousins
      
      Valesky
      
      Young
      
      aye wr (1)
      
      Dilan

Bill Amendments

Original

A (Active)

co-Sponsors

View additional co-sponsors

2015-S6962 - Details

Law Section:: Public Health Law
Laws Affected:: Add §3340, Pub Health L; add §3216-a, Ins L
Versions Introduced in Other Legislative Sessions:: 2017-2018: S7009
2019-2020: S3272
2021-2022: S6180
2023-2024: S4754

2015-S6962 - Summary

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

2015-S6962 - Sponsor Memo

                                 BILL NUMBER:  S6962

 TITLE OF BILL :

An act to amend the public health law and the insurance law, in
relation to the use of abuse-deterrent technology for opioids as a
mechanism for reducing abuse and diversion of opioid drugs

 PURPOSE :

To help prevent the abuse and diversion of opioid analgesic drugs by
ensuring that abuse-deterrent drugs approved by the FDA are dispensed
whenever prescribed and not substituted by non-abuse deterrent opioids
and that insurance coverage does not disadvantage drugs approved by
the FDA as abuse-deterrent.

 SUMMARY OF PROVISIONS :

Section 1 adds a new section 3340 to the Public health law to ensure
that an opioid analgesic drug product, brand or generic, with
abuse-deterrent technologies is not interchanged or substituted with
an opioid analgesic drug product lacking abuse-deterrent technologies
without obtaining a new prescription from the provider.

Section 2 adds a new section to the insurance law to: ensure that
abuse-deterrent opioid products are covered by insurance plans at

least the same levels as non-abuse-deterrent opioid products; ensure
that a patient is not required to take a non-abuse-deterrent opioid
before an abuse-deterrent version; and ensure that prior authorization
requirements are applied equally to abuse and non-abuse-deterrent
opioids.

Section 3 is the effective date of the bill.

 JUSTIFICATION :

While pain management is an important and integral part of the health
care system, abuse and diversion of opioids has necessitated the
implementation of various anti-abuse policies. These policies need to
be approached comprehensively by government, law enforcement, health
care providers and manufacturers and an important component is to
ensure that opioids incorporating abuse-deterrent technologies are
dispensed whenever possible.

The U.S. Food and Drug Administration (FDA) has recognized that the
development and implementation of abuse-deterrent technologies is an
important "step towards the goal of creating safer opioid analgesics."
In recently published FDA guidance on abuse-deterrent technologies for
opioids, the FDA provided that they "consider(s) the development of
these products a high public health priority."

Under this proposal, when a physician prescribes an opioid analgesic
drug that incorporates abuse-deterrent technologies, no substitution
or interchange shall be permitted for that drug without a new
prescription from their doctor or health care provider.

This proposal also recognizes that to further the goal of encouraging
the use of abuse-deterrent technologies as part of a broader plan to
reduce opioid addiction and abuse, it is imperative that insurance
coverage is applied equitably and does not provide a disincentive to
the use of abuse-deterrent opioids.

While New York State has been at the forefront of fighting
prescription drug abuse, it is critical that the State continue to
strengthen its laws and protect against abuse while enhancing the
integrity of its health care system. Enacting this proposal will be
consistent with these goals and with the priorities set out by the
FDA.

 LEGISLATIVE HISTORY :

Similar to S.5170A of 2015.

 FISCAL IMPLICATIONS :

None.

 EFFECTIVE DATE :
This act shall take effect after 120 days, and shall apply to all
policies and contracts issued, renewed, modified, altered or amended
on or after such date.

2015-S6962 - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  6962

                            I N  S E N A T E

                             March 10, 2016
                               ___________

Introduced  by  Sens.  HANNON,  AMEDORE,  BOYLE,  CROCI, GOLDEN, LARKIN,
  MARTINS, MURPHY, ORTT -- read twice  and  ordered  printed,  and  when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law and the insurance law, in relation
  to  the  use  of abuse-deterrent technology for opioids as a mechanism
  for reducing abuse and diversion of opioid drugs

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  The  public health law is amended by adding a new section
3340 to read as follows:
  S 3340. SUBSTITUTION OF OPIOIDS WITH  ABUSE-DETERRENT  TECHNOLOGY.  1.
(A)  NOTWITHSTANDING  THE  PROVISIONS  OF  SECTION  SIXTY-EIGHT  HUNDRED
SIXTEEN-A OF THE EDUCATION  LAW,  NO  PHARMACIST  SHALL  INTERCHANGE  OR
SUBSTITUTE  AN  ABUSE-DETERRENT  OPIOID ANALGESIC DRUG PRODUCT, BRAND OR
GENERIC, WITH AN OPIOID ANALGESIC DRUG PRODUCT  LACKING  ABUSE-DETERRENT
PROPERTIES   WHEN   THE  PRESCRIBER  WRITES  OR  ELECTRONICALLY  NOTATES
"DISPENSE AS WRITTEN" OR "DAW" ON THE PRESCRIPTION, WITHOUT OBTAINING  A
NEW PRESCRIPTION FOR A NON-ABUSE DETERRENT OPIOID DRUG FROM THE PRESCRI-
BER. ANY SUBSTITUTABLE OPIOID DRUG PRODUCT SHALL CONTAIN THE SAME OPIOID
ACTIVE  PHARMACEUTICAL  INGREDIENT  AND THE SAME DRUG RELEASE CHARACTER-
ISTICS WITH REGARD TO IMMEDIATE RELEASE, OR EXTENDED RELEASE LONG ACTING
PROPERTIES. A DETERMINATION OF INTERCHANGEABILITY BETWEEN TWO ABUSE-DET-
ERRENT OPIOID ANALGESIC  DRUG  PRODUCTS  SHALL  NOT  REQUIRE  THAT  BOTH
PRODUCTS  INCORPORATE THE SAME METHODS OF ABUSE-DETERRENCE, BUT THAT THE
OPIOID DRUG PRODUCTS HAVE THE SAME LEVEL OF  FDA-APPROVED  ABUSE  DETER-
RENCE LABELING CLAIMS.
  (B)  THE REQUIREMENTS OF PARAGRAPH (A) OF THIS SECTION SHALL NOT APPLY
TO A PHARMACIST DISPENSING MEDICATION IN THE INPATIENT HOSPITAL  SETTING
WHEN THE PRESCRIBED MEDICATION WILL BE ADMINISTERED TO THE PATIENT BY AN
EMPLOYEE OF THE HOSPITAL.
  2. DEFINITIONS. AS USED IN THIS SECTION:
  (A)  "OPIOID  ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE OPIOID ANAL-
GESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE TO SEVERE  PAIN  OR  OTHER
CONDITIONS, WHETHER IN IMMEDIATE RELEASE OR EXTENDED RELEASE LONG ACTING

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD14477-01-6

S. 6962                             2

FORM  AND  WHETHER  OR NOT COMBINED WITH OTHER DRUG SUBSTANCES TO FORM A
SINGLE DRUG PRODUCT OR OTHER DOSAGE FORM.
  (B)  "ABUSE-DETERRENT  OPIOID ANALGESIC DRUG PRODUCT" MEANS A BRAND OR
GENERIC OPIOID ANALGESIC DRUG PRODUCT APPROVED BY THE FEDERAL  FOOD  AND
DRUG ADMINISTRATION WITH ABUSE-DETERRENCE LABELING CLAIMS INDICATING ITS
ABUSE-DETERRENT PROPERTIES ARE EXPECTED TO DETER OR REDUCE ITS ABUSE.
  (C)  "INTERCHANGE OR SUBSTITUTION OF AN OPIOID DRUG" MEANS THE SUBSTI-
TUTION OF ANY ABUSE-DETERRENT OPIOID DRUG  PRODUCT,  BRAND  OR  GENERIC,
WITH AN OPIOID ANALGESIC DRUG LACKING ABUSE-DETERRENT PROPERTIES.
  (D)  "PHARMACIST"  INCLUDES  ANY PHARMACIST DISPENSING DRUGS UNDER THE
JURISDICTION OF THE STATE BOARD OF PHARMACY, INCLUDING BUT  NOT  LIMITED
TO,  COMMUNITY  PHARMACISTS  AND  PHARMACISTS  IN  MAIL ORDER PHARMACIES
LICENSED BY THE STATE TO DISTRIBUTE IN THE STATE.
  S 2. The insurance law is amended by adding a new  section  3216-a  to
read as follows:
  S 3216-A.  ACCESS TO ABUSE-DETERRENT OPIOID MEDICATIONS. (A) AN INSUR-
ANCE  CARRIER  OR  HEALTH  PLAN SHALL PROVIDE COVERAGE ON ITS FORMULARY,
DRUG LIST  OR  OTHER  LISTS  OF  SIMILAR  CONSTRUCT  FOR  AT  LEAST  ONE
ABUSE-DETERRENT  OPIOID  ANALGESIC  DRUG  PRODUCT  PER  OPIOID ANALGESIC
ACTIVE INGREDIENT.
  (1) COST-SHARING FOR BRAND NAME ABUSE-DETERRENT OPIOID ANALGESIC  DRUG
PRODUCTS  COVERED  PURSUANT  TO THIS SECTION SHALL NOT EXCEED THE LOWEST
COST-SHARING LEVEL APPLIED TO  BRAND  NAME  NON-ABUSE  DETERRENT  OPIOID
DRUGS COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (2)  COST-SHARING  FOR  GENERIC  ABUSE-DETERRENT OPIOID ANALGESIC DRUG
PRODUCTS COVERED PURSUANT TO THIS SECTION SHALL NOT  EXCEED  THE  LOWEST
COST-SHARING  LEVEL  APPLIED TO GENERIC NON-ABUSE DETERRENT OPIOID DRUGS
COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (3) AN INCREASE IN PATIENT COST-SHARING OR DISINCENTIVES FOR  PRESCRI-
BERS  OR DISPENSERS SHALL NOT BE ALLOWED TO ACHIEVE COMPLIANCE WITH THIS
SECTION.
  (B) ANY PRIOR-AUTHORIZATION REQUIREMENTS OR OTHER  UTILIZATION  REVIEW
MEASURES  FOR  OPIOID  ANALGESICS, AND ANY SERVICE DENIALS MADE PURSUANT
THERETO, SHALL NOT REQUIRE USE OF OPIOID ANALGESIC DRUG PRODUCTS WITHOUT
ABUSE-DETERRENT PROPERTIES IN ORDER  TO  ACCESS  ABUSE-DETERRENT  OPIOID
ANALGESIC DRUG PRODUCTS.
  (C) DEFINITIONS. AS USED IN THIS SECTION:
  (1)  "OPIOID  ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE OPIOID ANAL-
GESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE TO SEVERE  PAIN  OR  OTHER
CONDITIONS, WHETHER IN IMMEDIATE RELEASE OR EXTENDED LONG ACTING RELEASE
FORM  AND  WHETHER  OR NOT COMBINED WITH OTHER DRUG SUBSTANCES TO FORM A
SINGLE DRUG PRODUCT OR OTHER DOSAGE FORM.
  (2) "ABUSE DETERRENT OPIOID ANALGESIC DRUG PRODUCT" MEANS A  BRAND  OR
GENERIC  OPIOID  ANALGESIC DRUG PRODUCT APPROVED BY THE FEDERAL FOOD AND
DRUG ADMINISTRATION WITH ABUSE-DETERRENCE LABELING CLAIMS INDICATING ITS
ABUSE-DETERRENT PROPERTIES ARE EXPECTED TO DETER OR REDUCE ITS ABUSE.
  (3) "COST-SHARING" MEANS ANY COVERAGE LIMIT,  COPAYMENT,  COINSURANCE,
DEDUCTIBLE OR OTHER OUT-OF-POCKET PATIENT EXPENSE REQUIREMENTS.
  S 3. This act shall take effect on the one hundred twentieth day after
it  shall  have  become  a  law,  and  shall  apply  to all policies and
contracts issued, renewed, modified, altered or amended on or after such
date.

co-Sponsors

View additional co-sponsors

2015-S6962A (ACTIVE) - Details

Law Section:: Public Health Law
Laws Affected:: Add §3340, Pub Health L; add §3216-a, Ins L
Versions Introduced in Other Legislative Sessions:: 2017-2018: S7009
2019-2020: S3272
2021-2022: S6180
2023-2024: S4754

2015-S6962A (ACTIVE) - Summary

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

2015-S6962A (ACTIVE) - Sponsor Memo

                                 BILL NUMBER:  S6962A

 TITLE OF BILL :  An act to amend the insurance law, in relation to
the use of abuse-deterrent technology for opioids as a mechanism for
reducing abuse and diversion of opioid drugs

 PURPOSE :

To help prevent the abuse and diversion of opioid analgesic drugs by
ensuring that abuse-deterrent drugs approved by the FDA are accessible
to patients and that that insurance coverage does not disadvantage
access for patients to drugs approved by the FDA as abuse-deterrent.

 SUMMARY OF PROVISIONS :

Section 1 adds a new section 3216-a to the insurance law to ensure
patient access to abuse-deterrent opioid analgesic drugs by requiring
that a minimum of one opioid abuse-deterrent opioid analgesic drug per
opioid analgesic active ingredient is covered by insurance plans and
to ensure that a patient is not required to take a non-abuse deterrent
opioid before an abuse-deterrent opioid before an abuse-deterrent
version.

Section 2 is the effective date of the bill.

 JUSTIFICATION :

While pain management is an important and integral part of the health
care system, abuse and diversion of opioids has necessitated the
implementation of various anti-abuse policies. These policies need to
be approached comprehensively by government, law enforcement, health
care providers and manufacturers and an important component is to
ensure that opioids incorporating abuse-deterrent technologies are
dispensed whenever possible.

The U.S. Food and Drug Administration (FDA) has recognized that the
development and implementation of abuse-deterrent technologies is an
important "step towards the goal of creating safer opioid analgesics."
In recently published FDA guidance on abuse-deterrent technologies for
opioids, the FDA provided that they "consider the development of these
products a high public health priority."

To combat opioid misuse and abuse, the FDA is encouraging
manufacturers to develop abuse-deterrent formulations that when taken
as prescribed still provide appropriate pain relief, but
are-formulated to make it more difficult to alter the drug product for
purposes of misuse or abuse, such as making the product harder to
crush or liquefy in order to snort or inject. The FDA has provided
guidance as to the steps that a manufacturer can take to demonstrate
that an opioid drug product is formulated with abuse-deterrent
technologies and after rigorous testing has shown that the
abuse-deterrent formulation is expected to deter or reduce abuse of
the drug product. It is only after achieving successful results on
these tests that the FDA will allow for a drug product's label to
include claims based on demonstration of meaningful abuse-deterrent
properties.

This proposal recognizes that to further the goal of encouraging the
use of abuse-deterrent technologies as part of a broader plan to
reduce opioid addiction and abuse, it is imperative that insurance
coverage is applied equitably and does not provide a disincentive to
the use of abuse-deterrent opioids.

While New York State has been at the forefront of fighting
prescription drug abuse, it is critical that the State continue to
strengthen its laws and protect against abuse while enhancing the
integrity of its health care system. Enacting this proposal will be
consistent with these goals and with the priorities set out by the
FDA.

 LEGISLATIVE HISTORY :

New bill

 FISCAL IMPLICATIONS :

None

 EFFECTIVE DATE :
This act shall take effect on the 120th day, and shall apply to all
policies and contracts issued, renewed, modified, altered or amended
on or after such date.

2015-S6962A (ACTIVE) - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 6962--A

                            I N  S E N A T E

                             March 10, 2016
                               ___________

Introduced  by  Sens.  HANNON,  AKSHAR,  AMEDORE,  BOYLE, CROCI, GOLDEN,
  LARKIN, LATIMER, MARTINS, MURPHY,  ORTT  --  read  twice  and  ordered
  printed,  and  when printed to be committed to the Committee on Health
  -- committee discharged, bill amended, ordered  reprinted  as  amended
  and recommitted to said committee

AN  ACT to amend the insurance law, in relation to the use of abuse-det-
  errent technology for opioids as a mechanism for  reducing  abuse  and
  diversion of opioid drugs

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. The insurance law is amended by adding a new section 3216-a
to read as follows:
  S 3216-A.  ACCESS TO ABUSE-DETERRENT OPIOID MEDICATIONS. (A) AN INSUR-
ANCE CARRIER OR HEALTH PLAN SHALL PROVIDE  COVERAGE  ON  ITS  FORMULARY,
DRUG  LIST  OR  OTHER  LISTS  OF  SIMILAR  CONSTRUCT  FOR  AT  LEAST ONE
ABUSE-DETERRENT OPIOID  ANALGESIC  DRUG  PRODUCT  PER  OPIOID  ANALGESIC
ACTIVE INGREDIENT.
  (1)  COST-SHARING FOR BRAND NAME ABUSE-DETERRENT OPIOID ANALGESIC DRUG
PRODUCTS COVERED PURSUANT TO THIS SECTION SHALL NOT  EXCEED  THE  LOWEST
COST-SHARING  LEVEL  APPLIED  TO  BRAND  NAME NON-ABUSE DETERRENT OPIOID
DRUGS COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (2) COST-SHARING FOR GENERIC  ABUSE-DETERRENT  OPIOID  ANALGESIC  DRUG
PRODUCTS  COVERED  PURSUANT  TO THIS SECTION SHALL NOT EXCEED THE LOWEST
COST-SHARING LEVEL APPLIED TO GENERIC NON-ABUSE DETERRENT  OPIOID  DRUGS
COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (3)  AN INCREASE IN PATIENT COST-SHARING OR DISINCENTIVES FOR PRESCRI-
BERS OR DISPENSERS SHALL NOT BE ALLOWED TO ACHIEVE COMPLIANCE WITH  THIS
SECTION.
  (B)  ANY  PRIOR-AUTHORIZATION REQUIREMENTS OR OTHER UTILIZATION REVIEW
MEASURES FOR OPIOID ANALGESICS, AND ANY SERVICE  DENIALS  MADE  PURSUANT
THERETO, SHALL NOT REQUIRE USE OF OPIOID ANALGESIC DRUG PRODUCTS WITHOUT
ABUSE-DETERRENT  PROPERTIES  IN  ORDER  TO ACCESS ABUSE-DETERRENT OPIOID
ANALGESIC DRUG PRODUCTS.
  (C) DEFINITIONS. AS USED IN THIS SECTION:

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD14477-03-6

S. 6962--A                          2

  (1) "OPIOID ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE  OPIOID  ANAL-
GESIC  DRUG  CLASS  PRESCRIBED TO TREAT MODERATE TO SEVERE PAIN OR OTHER
CONDITIONS, WHETHER IN IMMEDIATE RELEASE OR EXTENDED LONG ACTING RELEASE
FORM AND WHETHER OR NOT COMBINED WITH OTHER DRUG SUBSTANCES  TO  FORM  A
SINGLE DRUG PRODUCT OR OTHER DOSAGE FORM.
  (2)  "ABUSE  DETERRENT OPIOID ANALGESIC DRUG PRODUCT" MEANS A BRAND OR
GENERIC OPIOID ANALGESIC DRUG PRODUCT APPROVED BY THE FEDERAL  FOOD  AND
DRUG ADMINISTRATION WITH ABUSE-DETERRENCE LABELING CLAIMS INDICATING ITS
ABUSE-DETERRENT PROPERTIES ARE EXPECTED TO DETER OR REDUCE ITS ABUSE.
  (3)  "COST-SHARING"  MEANS ANY COVERAGE LIMIT, COPAYMENT, COINSURANCE,
DEDUCTIBLE OR OTHER OUT-OF-POCKET PATIENT EXPENSE REQUIREMENTS.
  S 2. This act shall take effect on the one hundred twentieth day after
it shall have become  a  law,  and  shall  apply  to  all  policies  and
contracts issued, renewed, modified, altered or amended on or after such
date.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Senate Bill S6962

Share this bill

Sponsored By

Archive: Last Bill Status - Vetoed by Governor

Bill Amendments

co-Sponsors

2015-S6962 - Details

2015-S6962 - Summary

2015-S6962 - Sponsor Memo

2015-S6962 - Bill Text download pdf

co-Sponsors

2015-S6962A (ACTIVE) - Details

2015-S6962A (ACTIVE) - Summary

2015-S6962A (ACTIVE) - Sponsor Memo

2015-S6962A (ACTIVE) - Bill Text download pdf

Comments